Carfilzomib-Dexamethasone Combo Approved for Relapsed or Refractory MM
The U.S. Food and Drug Administration (FDA) has approved the combination of once-weekly carfilzomib with dexamethasone for the treatment of patients with relapsed or...
FDA Approves NGS-Based Test for Patients With ALL or MM
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal residual disease (MRD) in...
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...
Denosumab Versus Zoledronic Acid for Reducing Time to Skeletal Events in Multiple Myeloma
Approximately 90 percent of patients diagnosed with multiple myeloma (MM) present with bone lesions and are typically treated with zoledronic acid (ZA), a potentially...
Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients...
bb2121: Is CAR T-Cell Therapy Moving to Myeloma?
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...
Multiple Myeloma Outcomes Differ Based on Socioeconomic Factors
Despite the gains made in improving treatment for and care of patients with multiple myeloma (MM), disparities persist based on race and socioeconomic status....
Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095
More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...
BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma
In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...
Controversies in Myeloma: The Who, When, and Why of Treatment
The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...
Current Issue
October 2018, Volume 4, Issue 12
This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.
